Differences in evidentiary requirements for oncology drug effectiveness assessments among six European health technology assessment bodies — can alignment be improved?

References

• IQVIA. EFPIA patients W.A.I.T. Indicator 2021 survey [Internet]. 2022 [cited 2023 Aug 21]. Available from: https://www.efpia.eu/media/676539/efpia-patient-wait-indicator_update-july-2022_final.pdf.
   Google Scholar
• Tafuri G, Pagnini M, Moseley J, et al. How aligned are the perspectives of EU regulators and HTA bodies? A comparative analysis of regulatory-HTA parallel scientific advice. Br J Clin Pharmacol. 2016;82:965–973.
   PubMed Web of Science ®Google Scholar
• Kleijnen S, Lipska I, Alves TL, et al. Relative effectiveness assessments of oncology medicines for pricing and reimbursement decisions in European countries. Ann Oncol Internet. 2016 [cited 2019 Nov 26];27(9):1768–1775. doi: 10.1093/annonc/mdw233
   PubMed Web of Science ®Google Scholar
• Angelis A, Lange A, Kanavos P. Using health technology assessment to assess the value of new medicines: results of a systematic review and expert consultation across eight European countries. Eur J Health Econ. 2018;19(1):123–152. doi: 10.1007/s10198-017-0871-0
   PubMed Web of Science ®Google Scholar
• Wilking N, Bucsics A, Sekulovic LK, et al. Achieving equal and timely access to innovative anticancer drugs in the European Union (EU): summary of a multidisciplinary CECOG-driven roundtable discussion with a focus on Eastern and South-Eastern EU countries. ESMO Open. 2019;4(6):550. doi: 10.1136/esmoopen-2019-000550
   PubMed Web of Science ®Google Scholar
• Akehurst RL, Abadie E, Renaudin N, et al. Variation in Health technology assessment and reimbursement processes in Europe. Value Health Internet. 2017;20:67–76. doi: 10.1016/j.jval.2016.08.725
   PubMed Web of Science ®Google Scholar
• EFPIA. The root cause of unavailability and delay to innovative medicines the root cause of unavailability and delay to innovative medicines: reducing the time before patients have access to innovative medicines [Internet]. 2023. Available from: https://www.efpia.eu/media/602581/principles-on-the-transparency-of-evidencefrom-novel-pricing-and-payment-models.pdf.
   Google Scholar
• Fontrier AM, Visintin E, Kanavos P. Similarities and differences in Health technology assessment systems and implications for coverage decisions: evidence from 32 countries. Pharmacoecon Open Adis. 2022;6(3):315–328. doi: 10.1007/s41669-021-00311-5
   PubMed Web of Science ®Google Scholar
• Shah KK, Mestre-Ferrandiz J, Towse A, et al. A review of health technology appraisals: case studies in oncology. Int J Technol Assess Health Care. 2013;29(1):101–109. doi: 10.1017/S0266462312000669
   PubMed Web of Science ®Google Scholar
• Leyens L, Brand A. Early patient access to medicines: Health technology assessment bodies need to catch up with new marketing authorization methods. Public Health Genomics. 2016;19(3):187–191. doi: 10.1159/000446537
   PubMed Web of Science ®Google Scholar
• Wolters S, Jansman F, Postma M. Differences in evidentiary requirements between European Medicines Agency and European Health technology assessment of oncology drugs—can alignment be Enhanced? Value Health. 2022;25(12):1958–1966. doi: 10.1016/j.jval.2022.05.006.
   PubMed Web of Science ®Google Scholar
• Jansen C, Amesz B. Improving time to patient access to innovative oncology therapies in Europe. Vintura/EFPIA; 2020. https://www.efpia.eu/media/554646/every-day-counts-improving-time-to-patient-access-to-innovative-oncology-therapies-in-europe.pdf.
   Google Scholar
• Vogler S, Haasis MA, Dedet G, et al. WHO. MEDICINES REIMBURSEMENT POLICIES in EUROPE; 2018. https://iris.who.int/handle/10665/342220
   Google Scholar
• IQVIA. EFPIA patients W.A.I.T indicator 2019 survey. 2020;
   Google Scholar
• Facey K, Granados A, Meyer F, et al. Multi-stakeholder collaboration in generating the best possible knowledge – the SEED experience. Report of HTAi 2015 panel session. Health Technology Assessment International – Canada. 2015. [Internet]. [cited 2020 Mar 20]. Available from: https://htai.org/wp-content/uploads/2018/02/HTAi_SEED_Panel_Report_final.pdf.
   Google Scholar
• Barbuto V. European Commission. Update on the implementation of regulation (EU) 2021/2282 on Health technology assessment; 2022. https://www.eunethta.eu/wp-content/uploads/2022/11/20221118-EUnetHTA-stakeholder-meeting-FINAL.pdf
   Google Scholar
• Miksad RA, Zietemann V, Gothe R, et al. Progression-free survival as a surrogate endpoint in advanced breast cancer. Int J Technol Assess Health Care. 2008;24(4):371–383. doi: 10.1017/S0266462308080495
   PubMed Web of Science ®Google Scholar
• European Commission. Implementing the EU health technology assessment regulation; 2023. https://health.ec.europa.eu/system/files/2023-06/hta_regulation-implementation_factsheet_en.pdf
   Google Scholar
• Bloem L, Vreman R, Peeters N, et al. Associations between uncertainties identified by the European Medicines Agency and national decision making on reimbursement by HTA agencies. Clin Transl Sci Internet. 2021 [cited 2022 Apr 4];14(4):1566–1577. doi: 10.1111/cts.13027
   PubMed Web of Science ®Google Scholar
• Wang T, McAuslane N, Liberti L, et al. Building synergy between regulatory and HTA agencies beyond processes and procedures—can we effectively align the evidentiary requirements? A survey of stakeholder perceptions. Value Health Internet. 2018;21:707–714. doi: 10.1016/j.jval.2017.11.003
   PubMed Web of Science ®Google Scholar
• Ofori-Asenso R, Hallgreen CE, de Bruin ML. Improving Interactions between Health technology assessment bodies and regulatory Agencies: a Systematic review and cross-Sectional Survey on processes, progress, outcomes, and challenges. Front Med. Frontiers Media S.A. 2020;7:1–17. doi: 10.3389/fmed.2020.582634.
   Web of Science ®Google Scholar
• EUnetHTA WP7 research and analysis activity 1: final report an analysis of HTA and reimbursement procedures in EUnetHTA partner countries: final report.
   Google Scholar
• Association of European Cancer Leagues (ECL). LET’S TALK ACCESS! White paper on tackling challenges in access to medicines for all cancer patients in Europe. 2018.
   Google Scholar
• European Network for health technology assessment. EUnetHTA WP7 research and analysis activity 1: annex 1 Agency data an analysis of HTA and reimbursement procedures in EUnetHTA partner countries: annex 1 Agency data.
   Google Scholar
• Vreman RA, Bouvy JC, Bloem LT, et al. Weighing of evidence by Health technology assessment bodies: retrospective study of reimbursement recommendations for conditionally approved drugs. Clin Pharmacol Ther. 2019;105(3):684–691. doi: 10.1002/cpt.1251
   PubMed Web of Science ®Google Scholar
• Nicod E, Berg Brigham K, Durand-Zaleski I, et al. Dealing with uncertainty and accounting for social Value judgments in assessments of orphan drugs: evidence from four European countries. Value Health. 2017;20(7):919–926. doi: 10.1016/j.jval.2017.03.005
   PubMed Web of Science ®Google Scholar